Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.
about
An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employeesNarcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal.Responses to A(H1N1)pdm09 influenza vaccines in participants previously vaccinated with seasonal influenza vaccine: a randomized, observer-blind, controlled study.Influenza vaccines: a moving interdisciplinary field.A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.Matrix M(TM) adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4(+) T cell responses in man.Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studiesInvestigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccinationLong-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.Meta-analysis of the immunogenicity and tolerability of pandemic influenza A 2009 (H1N1) vaccines.Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants.Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvantFlexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial.Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or olderAntibody responses against influenza A(H1N1)pdm09 virus after sequential vaccination with pandemic and seasonal influenza vaccines in Finnish healthcare professionals.Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older.Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.Cellular Interferon Gamma and Granzyme B Responses to Cytomegalovirus-pp65 and Influenza N1 Are Positively Associated in Elderly.Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy.Influenza vaccines: T-cell responses deserve more attention.Inactivated influenza virus vaccines: the future of TIV and QIV.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events.Seeking help: B cells adapting to flu variability.Dissecting the hemagglutinin head and stalk-specific IgG antibody response in healthcare workers following pandemic H1N1 vaccination.Comment on "CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy".
P2860
Q30352329-1A7887DE-FEE4-4F5C-B806-F27E3583D744Q30355654-405E4A7B-281F-480B-A4D4-045F3096D005Q30356910-C91C0A4E-7C68-48B3-B1CD-75A9D7089673Q30362883-0A61CC75-4176-44CC-9DA2-A025147FBA1CQ30367695-35A5F091-074F-4DDC-8F49-600F65E15031Q30368934-5FF86C62-ED02-4BAF-9C1C-045924BAD77EQ30368937-B64E9DE6-923F-4A92-AC46-22ABBDEDBE16Q30369467-738EDD92-BB56-4794-8106-7D96438BF44BQ30374665-C1B67E35-A445-4705-9AD8-88F6400403D7Q30376727-E9B2B99F-8007-49B1-BB79-244AF27CF167Q30395263-6E7F012E-8196-4613-8259-501060CBCBC7Q30401398-13425CE3-C0D1-4446-A454-09EF98EB9E2DQ30407050-06FC297E-7F45-40E9-B6A4-E455011E4222Q30413695-D82EFB1A-1FCE-4457-9C52-74B60E83FB68Q30417273-AD1E0DCB-AFFF-4F72-A380-627C730DDA77Q30418297-C3BE6BE6-FB0E-4F67-A847-48B2C674F6B4Q30419564-6D956D34-AE65-4829-981D-AADEB6A9BD59Q30419943-26EF8F3A-484A-4DFF-BBED-D01E70337EE3Q30420571-09E4B39D-287E-4DE8-9235-97EC61F344EAQ30429185-A5300BE1-D52B-4A15-96DA-9974068CAD23Q34067461-DBB163E4-DB76-42CD-A9EA-300CDA94E671Q35887417-56646B0B-F960-4A48-8A9A-4BD1BA184F2AQ36786132-FD509A05-87D7-49BF-A4AE-6B18097C1B89Q37402532-D57C6ED1-BB9F-4ECB-98F5-E60A759EAABBQ38045918-375B9D92-5540-4994-BA76-4316D35AF983Q38683726-5D0F2DCC-36FE-4A34-AD26-571876BE5E5DQ40752357-7930096D-A854-4D01-B1BF-6DC572335EE0Q40846982-E59D860C-6FC6-4819-99D5-FEEBD3EF8E83Q42201392-013F0940-7AD4-4E9B-848C-7A7194B9205CQ47136777-C41CA0A8-5FE1-426B-BE18-6BB8217721D0Q51842727-123FF88E-8C73-4D99-A3EE-954EC833A6EC
P2860
Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Effect on cellular and humoral ...... randomized controlled trials.
@ast
Effect on cellular and humoral ...... randomized controlled trials.
@en
type
label
Effect on cellular and humoral ...... randomized controlled trials.
@ast
Effect on cellular and humoral ...... randomized controlled trials.
@en
prefLabel
Effect on cellular and humoral ...... randomized controlled trials.
@ast
Effect on cellular and humoral ...... randomized controlled trials.
@en
P2093
P2860
P356
P1476
Effect on cellular and humoral ...... o randomized controlled trials
@en
P2093
Emmanuel Hanon
Fien De Boever
François Roman
Geert Leroux-Roels
Julie Willekens
Karl Walravens
Walthère Dewé
P2860
P304
P356
10.1128/CVI.00480-10
P577
2011-03-30T00:00:00Z